Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis

被引：2
|
作者：
Pogosova, Nana [1 ]
Bosch, Jacqueline
Bhatt, Deepak L. [4 ]
Fox, Keith A. A. [5 ]
Connolly, Stuart J. [2 ,3 ,6 ]
Alings, Marco [7 ]
Verhamme, Peter [8 ]
Muehlhofer, Eva [9 ]
Shestakovska, Olga [2 ]
Yusuf, Salim [2 ,3 ,6 ]
Eikelboom, John W. [2 ,3 ,6 ]
机构：
[1] Natl Med Res Ctr Cardiol, Moscow, Russia
[2] Populat Hlth Res Inst, Hamilton, ON, Canada
[3] McMaster Univ, Hamilton, ON, Canada
[4] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
[5] Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland
[6] Hamilton Hlth Sci, Hamilton, ON, Canada
[7] Amphia Ziekenhuis & WCN, Utrecht, Netherlands
[8] Univ Leuven, Leuven, Belgium
[9] Bayer AG, Wuppertal, Germany
来源：
CIRCULATION | 2022年 / 145卷 / 25期
关键词：
aspirin; coronary artery disease; peripheral artery disease; rivaroxaban; venous thromboembolism;
D O I：
10.1161/CIRCULATIONAHA.122.059405
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1875 / 1877
页数：3
相关论文
共 50 条
  • [31] Rivaroxaban versus Aspirin in Prevention of Venous Thromboembolism: A Meta-Analysis of 9 Randomized Controlled Trials comprising 7,656 Patients
    Xie, Jian
    Jiang, Mingyang
    Lin, Yunni
    Deng, Huachu
    Xie, Xiaoyong
    Li, Lang
    THROMBOSIS AND HAEMOSTASIS, 2019, 119 (09) : 1517 - 1526
  • [32] Experience of a combination including indinavir 400 mg plus ritonavir 200 mg twice daily in HIV-infected patients: pharmacokinetic data
    Solas, C
    Petit, N
    Orticoni, M
    Durand, A
    Gastaut, JA
    Lacarelle, B
    PATHOLOGIE BIOLOGIE, 2002, 50 (09): : 565 - 567
  • [33] In patient with symptomatic peripheral arterial disease who had undergone lower-extremity revascularization, does rivaroxaban 2.5 mg twice daily plus aspirin reduce the composite risk of acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke or cardiovascular death compared to aspirin alone while being safe?
    Lanthier, L.
    Huard, G.
    Plourde, M. -E.
    Cauchon, M.
    REVUE DE MEDECINE INTERNE, 2020, 41 (08): : 571 - 572
  • [34] MPFF 1000 mg chewable once daily vs. MPFF 500 mg twice daily in chronic venous disease: the double-blind, randomized, non-inferiority CHEWY trial
    Mansilha, Armando
    Caldevilla, Hector
    Puskas, Attila
    Lucien, Arnaud
    Roby, Lucas
    Kirienko, Alexander
    INTERNATIONAL ANGIOLOGY, 2022, 41 (06) : 464 - 475
  • [35] Clinical efficacy and safety of a new 1000-mg suspension versus twice-daily 500-mg tablets of MPFF in patients with symptomatic chronic venous disorders: a randomized controlled trial
    Carpentier, Patrick
    van Bellen, Bonno
    Karetova, Debora
    Hanafiah, Harunarashid
    Enriquez-Vega, Elizabeth
    Kirienko, Alexander
    Dzupina, Andrej
    Sabovic, Miso
    Reina Gutierez, Lourdes
    Subwongcharoen, Somboom
    Tuzun, Hasan
    Maggioli, Arnaud
    INTERNATIONAL ANGIOLOGY, 2017, 36 (05) : 402 - 409
  • [36] BUDGET IMPACT OF RIVAROXABAN 2.5MG IN COMBINATION WITH ASPIRIN IN TREATMENT OF PATIENTS WITH CORONARY ARTERY DISEASE (CAD) OR PERIPHERAL ARTERY DISEASE (PAD) IN GREECE
    Kalogeropoulou, M.
    Gkouvitsos, I
    Barlogiannis, T.
    Bowrin, K.
    Briere, J. B.
    Millier, A.
    Karabis, A.
    VALUE IN HEALTH, 2019, 22 : S553 - S553
  • [37] EffectiVeness and safety of rivaroxaban therapy in daily-care patients with unusual venous thromboembolism - results of the prospective dresden NOAC registry (NCT01588119)
    Tittl, L.
    Marten, S.
    Hecker, J.
    Beyer-Westendorf, J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 : 28 - 28
  • [38] Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients
    Turpie, Alexander G. G.
    Lensing, Anthonie W. A.
    Fuji, Takeshi
    Boyle, Duane A.
    BLOOD COAGULATION & FIBRINOLYSIS, 2009, 20 (02) : 114 - 121
  • [39] Assessment of clinical and economic impact of rivaroxaban plus aspirin vs. aspirin alone as a secondary prophylaxis in patients with chronic and symptomatic peripheral arterial disease in the United States
    Shah, Anshul
    Dabbous, Firas
    Shah, Surbhi
    Ashton, Veronica
    Kharat, Akshay
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 10 - 15
  • [40] Safety, efficacy and pharmacokinetics of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis
    Rolla, Valeria Cavalcanti
    da Silva Vieira, Maria A.
    Pinto, Douglas Pereira
    Lourenco, Maria C.
    de Jesus, Carlos da Silva
    Morgado, Mariza Goncalves
    Ferreira Filho, Milton
    Werneck-Barroso, Eduardo
    CLINICAL DRUG INVESTIGATION, 2006, 26 (08) : 469 - 479
12345